Life Sciences Archive » January, 2020

Life Sciences - January, 2020

386 articles

• Dental Supplier Resends Arbitration Row To High Court
• Hemp Heavyweights Urge USDA To Ease Testing Rules
• 13 Firms To Steer 7-IPO Week Led By Another $1B-Plus Deal
• Novo Nordisk Investors Win Cert. In Insulin Kickback Suit
• Meet The Attorneys Taking On Juul In The MDL
• Most Lawyers Do Not Understand How AI Works
• 3 Health Care Cos. Begin Trading After IPOs Totaling $420M
• UK Litigation Roundup: Here's What You Missed In London
• 4 Considerations When Moving To A New Law Firm
• Silk Road Figure Admits To Narcotics Conspiracy Count
• Funds Say Allergan Wants '2nd Bite At Apple' Dismissal
• Feds, AbbVie Agree Drug Delay Case Belongs In 3rd Circ.
• NJ Court Declines To Toss Sandoz Suit Over Blocked Generic
• J&J Says Workers Misinterpreted High Court's IBM Ruling
• LabCorp Preserves Win In Blood-Testing Contract Row
• Altria Wipes Another $4.1B From Value Of Juul Stake
• Medical Device Startup's Ex-CEO Convicted For Looting $3M
• J&J Owes $344M For False Mesh Marketing, Calif. Judge Says
• Fresh EU Cybersecurity Issues For Medical Device Cos.
• Goodwin-Led Cancer Drug Co. Prices Upsized $201M IPO
• Patent Strategies For Chinese Approval Of Medical Devices
• Days Before Merger, Drinker Biddle Adds 4 IP Partners In Colo.
• A Modest Plan To Streamline Civil Cases In LA Superior Court
• Opioid MDL's Pharmacy Bellwether Trial Nudged To November
• EU High Court Glaxo Ruling Validates Pay-For-Delay Fines
• 3rd Circ. Won't Nix Conviction In $3M Insider Trading Plot
• Legal Org. Urges 4th Circ. To Ditch E-Cig Application Deadline
• Walgreens Faces Claims It Kept $35M From 'Pharma Bro' Co.
• FDA's Asbestos-In-Talc Finding Doesn't Upend J&J Trial Win
• J&J, Retailers Hit With Prop 65 Suit Over Talc
• Takeda Gets Go-Ahead To Appeal Actos Rulings At 2nd Circ.
• Fed. Circ. Revives Galderma Patents Challenged By Teva
• Pharma CEO Asks Judge To Toss Opioid Trafficking Charge
• Nutrition Claims Trimmed In Walmart False Ad Suit
• What Courts Are Saying About Litigation Finance Disclosure
• State AGs Diss Pfizer's Effort To Flee Price-Fixing MDL
• Cannabis Grower Wants To Toss Tech Developer's Wage Suit
• Boston Scientific Ruling Clarifies M&A Termination Rights
• US-China Trade Deal Will Help IP Owners
• Full 3rd. Circ. Won't Retread Avandia Marketing Decision
• CBD Risks Linger Despite Farm Bill, USDA Hemp Rules
• Clark Hill Can't Dodge Ex-Client's Malpractice Suit
• Novartis, Armed With New IP, Again Sues Over $3B MS Drug
• Insys Founder Says 'Drug Dealer' Accusation Biased Jury
• Quit Saying Purell Prevents Ebola, FDA Tells Sanitizer Co.
• Del. Judge Orders Rework For Melinta Ch. 11 Sale Plan
• Full Fed. Circ. Rejects Sanofi's Bid To Expand Arthrex To All
• Pa. Justices To Weigh Release Of Cannabis License Info
• Mass. Bill Would Give State More Control Over Pot Business
• Insurer Says Worker's Medical Pot Claim Barred By Fed. Law
• 'Chastened' Atty Apologizes For Takeda, BakerHostetler Suit
• Opioid MDL Special Master Sets Data Production Guidelines
• Japanese Pharma Co. Ordered To Pay $1.7M In Atty Fees
• Chubb Unit Needn't Cover Lab's $3.3M TCPA Deal
• Texas Justices Weigh Reach Of Forum Choice In Deals
• Full Fed. Circ. Told Patents Can't Render Themselves Obvious
• Surefire Marketing Methods To Build Your Legal Practice
• Zogenix Slips Seizure Drug Stock-Drop Claims For Now
• Insys Exec Can't Delay 33-Month Prison Sentence, Gov't Says
• What The US-China Trade Deal Means For Drug Cos.
• DOJ Details Allscripts Unit's 'Abhorrent' Opioid Kickback Plot
• Stryker Can't Move Ex-Worker's Suit From Calif.
• City Can't Stop Medical Pot Shop From Going Recreational
• CBD Investor's Fraud Suit Tossed After Failure To Lawyer Up
• Calif. Judge Allows Latest EPA Report In Next Roundup Trial
• State Courts Split Over Workers' Medical Pot Reimbursements
• Insys Doc Who Lied About Ex-Colleagues Gets Nearly 5 Years
• Health Hires: Latham, Husch Blackwell, Verrill Dana
• Five Companies Jolt IPO Pipeline With Deals Totaling $560M
• Claims Trimmed In Vitamin Shoppe Supplement Defect Suit
• 3rd-Party Funding Of FCA Cases Comes Under DOJ Scrutiny
• Allergan Divests To Get FTC Greenlight For $63B AbbVie Deal
• Pharmacies Can't Escape Public Nuisance In Opioid MDL
• Real Estate Rumors: Ladder, Horizon, BTI
• Drug Packaging Co. Accused Of Violating Workers' Privacy
• Drug Developer PPD Targets $1.53B For Public Debut
• Setting Boundaries: An Essential Skill For Lawyers
• Pharma Cos. Push 9th Circ. To Pause Calif. Pay-For-Delay Law
• 2nd Circ. Ruling Makes Messy Insider Trading Law Worse
• J&J CEO Denies Cashing In Options Was Linked To Exposé
• 'Pharma Bro' Accused Of Monopolizing Life-Saving Drug
• Sorrento Therapeutics Says $1B Bid Is Too Low
• Jefferies Slips Biotech Investors' Negligence Claims
• FDA Tells 4th Circ. To Axe E-Cig Apps Deadline Appeal
• Insys Shows RICO As Good For Kapoor As For Whitey Bulger
• AmerisourceBergen Wants Del. Justices On Opioid Doc Fight
• J&J Workers Say Justices' IBM Ruling Backs Their ERISA Row
• Allergan Cleared Of Misconduct At USPTO In Juvederm Spat
• Unions Find Organizing Cannabis Industry A Bumpy Road
• High Court Again Pauses Dental Dispute Ahead Of Trial
• FCA's Epic Run In 2010s Will Be Hard To Match In 2020s
• Sanofi, Mylan Spar Over Surescripts Ruling In EpiPen Fight
• Calif. Wants Pot Shops To Post QR Codes Amid Vaping Crisis
• NJ Man Ducks Prison For Trading On Tip From Ex-NY Rep.
• Bankruptcy Judge OKs $1.3M Bonus For Purdue CEO
• Gilead Says CDC Broke Promises After Taking Free HIV Drugs
• Clock Has Run Out For Hair-Loss Patients In Chemo MDL
• Roundup Deal Talks Stop St. Louis Trial Before It Starts
• ABA Rules For Departing Attys Set Unprecedented Limits
• MLB Accused Of Singling Out Health Food Co.
• Eli Lilly Taps WellCare Health GC For Top Lawyer Spot
• Seven Firms To Steer 5 IPOs Exceeding $1.8B To End January
• Ex-Perrigo Exec Slips Investor Suit Over Irish Audit
• McKesson, Stockholders Reach $175M Deal In Opioid Suit
• Calif. Appeals Court Won't Revive J&J Talc Suit
• Ex-Congressman's Son Dodges Prison For Insider Trading
• Refusal To End Kickback Suit 'Odd,' 7th Circ. Judge Says
• 4 Takeaways From Roundup Jury Selection In St. Louis
• Assertio Blasts Rival's Bid To Shorten Nucynta Injunction
• Cannabis Dispensaries, Customers Exposed In Data Breach
• USPTO Concerned Fed. Circ. Is Invoking Arthrex 'Reflexively'
• Rockwell Inks $3.7M Investor Deal Over Dialysis Drug Claims
• Insys Founder John Kapoor Gets 5½ Years
• Synthorx Investor Seeks To Probe $2.5B Sanofi Deal Proposal
• CBD Buyer Fights Fla. Retailer's Bid To Toss False Ad Suit
• 3 Firms Steer As Elanco Raises $1.3B For Animal Biz Buy
• Zantac Users Pile On Cancer Claims Ahead Of JPML Hearing
• Insys VP Who Dressed As Dancing Opioid Gets 2 Years
• Ex-Md. Lawmaker Admits Guilt In Medical Pot Bribery Scheme
• US Trustee Targets Bonuses In Antibiotics Firm's Ch. 11
• ECJ Adviser's Glaxo Opinion A Boost For Pay-For-Delay Fines
• Teva Scores Earliest Generic License For Allergan's Linzess
• 7th Circ. Asked To Keep Ind. 'Smokable Hemp' Ban Paused
• Bristol-Myers Wants $1.5B From Gilead After Cancer IP Trial
• 7th Circ. Mulls Restoring $3M Verdict For Reed Smith Widow
• Nissan Ex-CEO Illustrates Do's And Don'ts Of Image Repair
• Senators Unveil Bill Requiring Vape Cos. To Pay FDA
• Cooperating Insys CEO Gets 2½ Years In Prison
• Insys Exec Gets 1 Year As Atty Slams 'Salacious' Prosecution
• 4th Roundup Trial Kicks Off On Monsanto's Home Turf
• Ex-Insys Exec Blasts Big Pharma For Exploiting Women
• Rite Aid Investors Challenging Walgreens Merger Win Cert.
• McKesson Beats Antitrust-Linked Derivative Suit, For Now
• Dialysis Co. Says Revenue Gains Doom Investor Class Claims
• Jury Absolves Ethicon In Pelvic Mesh Suit
• Health Care Firms Heat Up Jan. IPO Pipeline With 3 Offerings
• Arthrex, S&N Push Full Fed. Circ. To Review PTAB Ruling
• Mo. Medical Marijuana Co. Scores Early Win In Zoning Battle
• Home Depot Can't Kill Roundup Cancer Warning Suit For Now
• Estimating Antitrust Impact, Damages Via Natural Experiments
• European Appeal Board OKs Revoking Broad CRISPR Patent
• Ex-NFLer Will Take Pot Decriminalization Bid To High Court
• ITC Decision Shows Importance Of Public Interest For Biotech
• FDA Focus: What Ropes & Gray's Practice Chair Is Watching
• Drug Buyers Say Ranbaxy Can't Have '11th Bite' At Dismissal
• Medical Device Co. Accused Of Upending $2B VA Contract
• 2 Insys Execs Get Less Than 3 Years In Opioid Kickback Case
• High Court ERISA Case Has States, Pharmacies On Edge
• Surescripts Can't Sink FTC's Monopoly Case
• Fresenius, Akorn Set To Fight Over Busted Tie-Up's $117M Tab
• USPTO Slams Arthrex Call To Strike Down IPRs At Fed. Circ.
• Ex-NY Congressman Gets Over 2 Years For Insider Trading
• Vape Injury Outbreak Mainly Tied To THC Products, CDC Says
• Hoffmann-La Roche Says Tamiflu FCA Suit 'Ignores Reality'
• 6th Circ. Is Told Opioid MDL Judge Flouting Court Rules
• Pulling Up Stakes: Sidley, Baker Botts, Hogan Lovells
• Chancery Energizes Investor Bids To Probe Corporations
• 4 Companies Kick Off 2020 IPO Season After Raising $373M
• Chuck Norris, Wife Drop Claims MRI Drug Threatened Her Life
• Scrapped Experts Can't Return In NJ Accutane Case
• $8B Risperdal Verdict Slashed To $6.8M
• Merck Says Ax Of $2.5B Patent Win A 'Disaster For Innovation'
• Patient Can't Force Michigan To Tap New Pot Suppliers
• US-China Deal's Patent Rules Will Boost Branded Drug Cos.
• 3rd Circ. Won't Revive Ex-Plant Worker's FLSA Suit
• Ex-Analysts Admit They Helped In Doctor's Office Ad Scheme
• DOJ Clears Optometry Org To Expand Purchasing Power
• 9th Circ. Won't Revive Cymbalta Users' Suit Against Eli Lilly
• Vape Group's Challenge To FDA's E-Cig Policy Falls Flat
• 6th Circ. Overturns Atty Sanctions In Medical Device Suit
• Gilead Hit With Another Antitrust Suit Over HIV Drugs
• HHS Drug Import Proposal Is Unlikely To Succeed
• Deals Rumor Mill: Albertsons, Springer Nature, DuPont
• 5 Key Issues Raised In Most CBD Product Class Actions
• Hospira Says Its $70M Loss Makes IP Safe Harbor 'Illusory'
• How Associate Life Has Evolved Over The Past Decade
• Frazier Healthcare Amasses More Than $617M For Latest Fund
• Brown Rudnick Wants $300M Malpractice Suit Tossed
• Insys Wins OK For Ch. 11 Plan With Opioid Recovery Trust
• Senate Sends North America Trade Deal To Trump
• Liberty Aims To Preserve Win In Pharmacy's Painkiller Suit
• BGI's Counterpunch Against Illumina Draws Mixed Reaction
• PTAB Weighs Sanofi Insulin Pen Patents In Mylan IP Row
• Audit Shows Minn. Regulators Can't Keep Up With Medical Pot
• J&J Can't Keep CEO Off Stand At Talc Asbestos Trial
• ResMed Settles FCA Suits Over Referral Fraud For $39.5M
• New Data Shows 100B Opioid Pills Flooded U.S. Over 9 Years
• How The US Plans To Enforce Its New Trade Deal With China
• FTC Tells 3rd Circ. AbbVie Pay-For-Delay Case Axed Too Early
• Ex-Attys Can't DQ New Counsel In $350M Shire Deal
• Del. Justices Weigh If Partnership Change Kills Standing
• Bayer Says 27K Essure Suits Can't Head 'Full-Steam' To Trial
• GSK Seeks To Forgo Trial In First Zofran MDL Bellwether
• What's Changed And What's The Same In Final CFIUS Rules
• US-China Trade Deal Aims To Bolster IP Protection
• Where The Fight Over FTC's Enforcement Authority Stands
• 2nd Circ. Ruling Could Lower Bar For Insider Trading Charges
• Gov't Initiatives May Boost Health Coverage For Genetic Tests
• 7th Circ. Lets Firms Take Share Of Bayer Settlement
• Son Of Ex-Ariad Pharma Director Guilty Of Insider Trading
• 7th Circ. Upholds $20M Pelvic Mesh Award Against J&J
• Biotech Firm NantHealth's CEO Can't Escape Stockholder Suit
• J&J Talc Victim At Death's Door Opens Damages Trial
• Opioid Overdose Deaths On Decline, States Say
• UK Pharma Co. Scores Patent For Magic Mushroom Treatment
• Sheppard Mullin Nabs Life Sciences Atty From Paul Hastings
• Feds Say 'Concise' Charges Against Ex-Theranos Exec Suffice
• Viagra MDL Doomed As Plaintiffs' Experts Booted, Pfizer Says
• Justices Eyeing Dental Arbitration Dispute Ahead Of Trial
• Prevagen False Ad Case Ends In Mistrial After Jury Deadlocks
• Lawmakers Told Lack Of Research Belies Pot's Risks, Benefits
• House Bill Would Let FDA Regulate CBD As A Supplement
• What Pa. Employment Suit Means For Medical Cannabis Users
• OFAC's New Iran Sanctions May Not Signal Seismic Change
• USMCA Trade Deal Slated For Final Passage This Week
• SmileDirect Claims Calif. Dental Board Continuing Harassment
• Drug Pricing: What Happened In 2019, What To Watch In 2020
• 2019 Trends In DOJ Civil Health Care Fraud Cases
• Health Tech Boom In 2020s Will Test Fraud, Privacy Laws
• NJ Appeals Court Shuts Down Injury Suit Over Bayer's Essure
• Full Fed. Circ. Won't Eye PTAB Order Junking Suboxone IPRs
• Biosimilar Patent Litigation May Be On The Rise In 2020
• Startup's CEO Stole Investor Cash For Maserati, Jury Told
• J&J CEO Must Take Stand At NJ Talc Asbestos Trial
• High Court Slams Door On Pleas To Redo Patent Eligibility
• Woman Slams Zimmer's Bid To Shake Off Hip Implant Suit
• Amid FDA Warnings, Hemp Companies Rethink CBD
• Fla. Pot Co. Says It Was Smeared In Short-Selling Scheme
• NY Court Tosses State's Ban On Flavored Vape Liquid
• Feds Dispute Ariad Insider Suspect's 'Wrong Man' Theory
• Supreme Court Rejects 10 Patent Cases
• FDA Slams Theranos Execs' 'Unprecedented' Doc Bid
• Why Reformers Want Disclosure Of 3rd-Party MDL Funding
• The Evolving Legality Of Lesser-Known Cannabis Compounds
• Okla. AG Sues Opioid Distributors For Ignoring Red Flags
• Surescripts Says High Court Petitions Could Resolve FTC Row
• DC Circ. Seems Poised To Block Trump's Drug Pricing Rule
• Judging A Book: Dyk Reviews 'Democracy And Equality'
• Ex-Insys Exec Gets Nearly 3 Years For Opioid Kickbacks
• Insys Judge Wonders If Potential Punishment Is Too Harsh
• AmerisourceBergen Loses Bid To Shield Opioid Docs
• The Firms That Dominated In 2019
• Law360 Names Practice Groups Of The Year
• Deal Makers Head To JP Morgan Conference In Bullish Mood
• Zimmer Wants Pa. Defective Hip Implant Case Tossed Again
• Del. Supreme Court Lets $3.8B Ligand Note Fix Stand
• Split Fed. Circ. Backs PTAB Ax Of Genentech Cancer Drug IP
• EEOC Says Sanofi Firing Dispute Should Have Gone To Trial
• 8th Circ. Nixes Class Arbitration Bid In Benefit Manager Row
• Reviewing 2019's White Collar Cases And Controversies
• High Court Wades Into ERISA Drug-Pricing Battle
• 'Polite F-U' Email Stays In States' Drug Price-Fixing Case
• Taxation With Representation: Ropes, Fried Frank, Weil
• Okla. AG, Endo Reach $8.75M Deal Over Opioids
• How States Are Responding To The Insulin Price Crisis
• Judge Orders New Trial In Cook Medical Vein Filter Bellwether
• PE Fund Floats Sorrento An Offer At Roughly $1B Valuation
• Pa. Lab Owner Guilty Of Paying Kickbacks For Medicare Tests
• Mass. Gene Therapy Co. Nabs $110M Series C Financing
• What The Budget Bill Has In Store For Medical Cos.
• 7 Insider Tips For Working With In-House Counsel
• EU Clears $63B AbbVie-Allergan Deal With Drug Sale
• Weil, Fenwick Guide $1.1B Deal For Calif. Biopharma Co.
• Juul Says Investor Waived His Right To Inspect Its Books
• Apple Hit With IP Suit Over Watch's Health Data Tracking Tech
• Calif. 'Cobra Sexual Energy' False-Ad Class Gets 2nd Wind
• 1st Circ. Says Ariad Executive May Have Biased Ex's Jury
• Chubb Says Insys Ch. 11 Plan Unclear On Insurance Terms
• Fed. Circ. Casts Doubt On Novartis MS Drug PTAB Win
• Health Care Fraud Made Up Bulk Of Feds' $3B Recovery In '19
• 'Horsie' Analogy Stampedes Through Fed. Circ. Patent Hearing
• CBD Retailer Says Gummy Potency Was Within 'Safe Harbor'
• Full Fed. Circ. Won't Review Nix Of 23andMe Patent
• Everything You Need To Know About Arthrex
• FDA To Hold Public Forum On Testing For Asbestos In Talc
• Swedish Biotech Firm Confidentially Files For US IPO
• USMCA Trade Deal Could Get Senate Vote Next Week
• Medical Marijuana To Be On Mississippi Ballot
• 50 Years Later, Interpretive Challenges Remain For RICO
• Brenntag Accused Of Wasting Money On Lousy 401(k)
• Fed. Circ. Backs Fresenius Win Over Hospira Sedative Patent
• Top 5 Drug And Medical Device Developments Of 2019
• Ethicon Beats Most Claims In Defective Pelvic Mesh Suit
• Investment Pro Faces New Fraud Charges Over $3.5M Offering
• Biopharma Co. Gets Nod For $4.5M Ch. 11 Sale Of Drug Rights
• Fed. Circ. Patent Decisions In 2019: An Empirical Review
• Swiss Trader's Trial Testimony Prompts Goldman Sachs Probe
• States Should Not Follow ABA On Attorney Conduct Rules
• Jury In False Ad Trial Told Memory-Boosting Pill Is A Lie
• Former Medical Device Co. Workers Say Firing Was Retaliation
• Investor Alleges Juul Executives Caused $20B Drop In Value
• Pfizer Beats False-Ad Suit Over FDA Approval Of Epinephrine
• Drug Buyers 'Astounded' As Celgene Axes $55M Antitrust Deal
• Cooperator Tells Jury He Barely Knew Ariad Insider Suspect
• ACA Insurer Wants CVS To Reveal Discounted Drug Prices
• Saxena White Scores Lead In Chemours Stock-Drop Suit
• Investors Say Chancery Wrong To OK $3.8B Ligand Note Fix
• Online Vape Companies Can't Sell Flavored Products In Mass.
• 9th Circ. Says Woman Who Stabbed Ex Can't Blame Lexapro
• Bristol-Myers, Sanofi Sue Hawaii AG Over Drug Promo Limits
• Fed. Circ. Affirms PTAB Ax Of AbbVie's Humira Patent
• 5th Circ. Won't Halt Dental Supply Case For High Court Review
• DOJ Corporate Plea Deals Face Increased Judicial Resistance
• How Courts And Litigants Can Benefit From Special Masters
• Winning An Unwinnable PTAB Rehearing
• Fed. Circ. Partially Revives Amgen's Sensipar Patent Fight
• J&J's Talc Trial Deal Shows Power Of FDA's Asbestos Finding
• Sarepta Investors Sue In Delaware Over Drug Risk Disclosures
• Whistleblower Fights Safeway's Bid To End Drug Price Suit
• Federal Investigators Can Intervene In Perrigo Takeover Row
• Medical Pot Co. Blasts Licensing Rules Before Fla. High Court
• 'Opioid Babies' Seek Class Cert. In MDL
• Dental Supply Co. Making Last Arbitration Push Ahead Of Trial
• Accutane Users Tell NJ Panel Judge Wrongly Axed Experts
• Bankruptcy Courts Remain Inaccessible To Cannabis Cos.
• Uber Policy Calls For Refresher On ABA Confidentiality Rules
• AndroGel Antitrust Case Won't Get Moved To Georgia
• Allergan Accused Of Playing Dirty In Breast Implant MDL
• Ametek Inks $250M Reading Alloys Sale To PE-Backed Co.
• CVS, Walmart Look To Shift Blame To Doctors In Opioid MDL
• Investor Wants Judge Off Suit Over 'Shark Tank' Soap-Maker
• Ex-Goldman Sachs Banker Cops To Insider Trading
• Insys Execs Say Restitution Should Be $18.4M, Not $306M
• Pfizer Unit's Alleged Drug Supply Cuts Aren't Anticompetitive
• Fla. Jurors Told Pelvic Mesh Degraded Inside Woman's Body
• SEC Says Insys 3rd-Party Releases Should Be Opt-In
• Feds Have 'Wrong Man,' Ariad Insider-Trading Jury Hears
• Suit Claims Coppertone's 'Mineral' Label Deceptive
• New Mexico State Fair Settles Cannabis Free Speech Suit
• Allergan To Pay $300M To End Birth Control Antitrust Case
• Fenwick-Led Biotech Firm Joins Early 2020 IPO Hopefuls
• Rethinking Corporate Crisis And Litigation Communications
• Stericycle Escapes Funeral Homes' Suit Over Price Increases
• Class Cert. In 11th Circ. Supplement Case Comes With Limits
• Teva To Pay $54M To End FCA Suit Alleging Bribes To Doctors
• Johnson & Johnson Settles Calif. Talc Case Midtrial
• Medtronic Gets Patient's 'Defective' Pump Suit Trimmed
• Fla. Judge Pauses CBD Suit To Wait For Federal Rules
• 2 Health Care Cos. File IPOs Totaling $200M
• Generics Industry Urges Fed. Circ. To Fix Arthrex 'Disarray'
• Cancer Treatment Maker Sues Over Alleged 'Copycat' Device
• Gene Testing Lab Buys UBiome Patents, Samples For $7M
• Court Says Trucker's THC Suit Is Not A Federal Matter
• 2 Overlooked Advantages Of Hourly Fees
• 2nd Circ. Deals Blow To Ex-NFLer's Pot Decriminalization Suit
• Skadden-Led Chinese Biotech Launches $100M IPO In US
• Pharma Tech Co. Sues Hemp Consultant Over IP 'Sabotage'
• Monthly Merger Review Snapshot
• What To Expect In Patent Litigation This Year
• Washington State Latest To Target J&J Over Opioid Epidemic
• Wall Street Insider Trading Just Got Easier To Prosecute
• Fed. Circ. Says Bryson Rightly Axed Zohydro ER Patents
• Illumina, PacBio Call Off $1.2B Merger Amid FTC Probe
• NY AG Cuts Deal Over Opioid Overdose Nasal Spray Device
• Buyers Say Pfizer Falsely Labeled Heartburn Drug As Safe
• Actavis Sheds Some Claims But Can't Exit Testosterone Trial
• HUD Not Behind Cannabis Patient's Eviction, 9th Circ. Told
• 9th Circ. Won't Touch FCA Suit Over Off-Label Opioids
• Antibiotics Developer Plans Ch. 11 Sale To Escape $213M Debt
• Pharmacies Must Produce 14 Years Of Opioid Records In MDL
• FDA To Crack Down On Sale Of Some Flavored Vapes
• The Path To A Stable Reporting Culture For Life Sciences Cos.
• Some Clarity On Inventor-Employee Compensation In The UK
• Ranbaxy Wants 1st Circ. To Settle Generics Antitrust Question
• California Pay-For-Delay Ban Headed To 9th Circ.
• ArQule Investor Wants More Detail On $2.7B Merck Sale
• Chinese Pharma Co. Raises $90M For Respiratory Therapies
• 2020 May Be The Year Of The Great CBD Market Correction
• New York Cases To Watch In 2020
• Health And Life Sciences Policy To Watch In 2020
• Florida Legislation To Watch In 2020
• Top 6 Under-the-Radar Gov't Contract Decisions In 2019
• California Cases To Watch In 2020
• Opioid, Theranos Cases Among Key Trials To Watch In 2020
• New Jersey Litigation To Watch In 2020
• Patent Legislation To Watch In 2020
• Product Liability Legislation And Regulation To Watch
• 3 Cannabis Policy Trends To Watch In 2020
• Federal Tax Regs To Watch In 2020
• Illinois Cases To Watch In 2020
• Patent Cases To Watch In 2020
• International Tax Cases To Watch In 2020
• Life Sciences Cases To Watch In 2020
• The Most Closely Watched Merger Reviews Of 2020
• 5 Burning Questions Heading Into The 2020 IPO Market
• 5 Things To Watch In Litigation Finance This Year